Characterizing PALB2 intragenic duplication breakpoints in a triple-negative breast cancer case using long-read sequencing

被引:0
|
作者
Ban, Iulian O. [1 ]
Chabert, Alice [1 ]
Guignard, Thomas [2 ,3 ]
Puechberty, Jacques [2 ,3 ]
Cabello-Aguilar, Simon [1 ,4 ]
Pujol, Pascal [2 ]
Vendrell, Julie A. [1 ]
Solassol, Jerome [1 ,5 ]
机构
[1] Univ Montpellier, Ctr Hosp Univ CHU Montpellier, Dept Pathol & Oncobiol, Lab Biol Tumeurs Solides, Montpellier, France
[2] Arnaud de Villeneuve Hosp, Dept Med Genet, Montpellier, France
[3] Univ Montpellier, Ctr Hosp Univ CHU Montpellier, Lab Genet Chromos, Plateforme ChromoStem, Montpellier, France
[4] Ctr Hosp Univ CHU Montpellier, Montpellier BioInformat Clin Diag MOBID, Mol Med & Genom Platform PMMG, Montpellier, France
[5] Univ Montpellier, Inst Rech Cancerol Montpellier IRCM, Inst Canc Montpellier ICM, Montpellier, France
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词
PALB2; LGR; breast cancer; long-read sequencing; molecular alteration; MECHANISMS;
D O I
10.3389/fonc.2024.1355715
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Accurate identification and characterization of Large Genomic Rearrangements (LGR), especially duplications, are crucial for precise diagnosis and risk assessment. In this report, we characterized an intragenic duplication breakpoint of PALB2 to determine its pathogenicity significance. Methods: A 52-year-old female with triple-negative breast cancer was diagnosed with a novel PALB2 LGR. An efficient and accurate methodology was applied, combining long-read sequencing and transcript analysis for the rapid characterization of the duplication. Results: Duplication of exons 5 and 6 of PALB2 was validated by transcript analysis. Long-read sequencing enabled the localization of breakpoints within Alu elements, providing insights into the mechanism of duplication via non-allelic homologous recombination. Conclusion: Using our combined methodology, we reclassified the PALB2 duplication as a pathogenic variant. This reclassification suggests a possible causative link between this specific genetic alteration and the aggressive phenotype of the patient.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Successful Treatment of Concurrent Follicular Lymphoma and Triple-Negative Breast Cancer Using Rituximab Plus Nab-Paclitaxel and Cisplatin: A Case Report and Literature Review
    Zhu, Zhou
    Zhou, Na
    Yu, Shuangni
    Gao, Xin
    Cheng, Xin
    Wang, Yingyi
    Bai, Chunmei
    ONCOTARGETS AND THERAPY, 2023, 16 : 905 - 911
  • [42] Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells
    Yali Han
    Wei Xie
    De-Gang Song
    Daniel J. Powell
    Journal of Hematology & Oncology, 11
  • [43] Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells
    Han, Yali
    Xie, Wei
    Song, De-Gang
    Powell, Daniel J., Jr.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [44] ImmunoPET imaging of Trop2 expression in triple-negative breast cancer using [64Cu]Cu-NOTA-Trodelvy-F(ab')2
    Huang, Wenpeng
    Zhang, Yuwei
    Xiao, Xiaoyan
    Yang, Qi
    Mixdorf, Jason C.
    Sun, Xinyao
    Engle, Jonathan W.
    Fan, Yu
    Li, Liming
    Kang, Lei
    Cai, Weibo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2025,
  • [45] Long-term oncologic outcome of unselected triple-negative breast cancer patients according to BRCA1/2 mutations: a comprehensive single institution study
    Chung, Soo Yeon
    Ryu, Jai Min
    Jung, You Jin
    Kim, Yeon Jin
    Kim, Hye Jin
    Nam, Seok Jin
    Kim, Seok Won
    Yu, Jonghan
    Chae, Byung Joo
    Lee, Jeong Eon
    Lee, Se Kyung
    Kim, Sung-Won
    Kim, Eun Young
    CANCER RESEARCH, 2023, 83 (05)
  • [46] Long non-coding RNA ZEB2-AS1 promotes the proliferation, metastasis and epithelial mesenchymal transition in triple-negative breast cancer by epigenetically activating ZEB2
    Zhang, Guoxin
    Li, Hongli
    Sun, Ruimei
    Li, Peirui
    Yang, Zhiyi
    Liu, Yuanyuan
    Wang, Zhaoyan
    Yang, Yuling
    Yin, Chonggao
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2019, 23 (05) : 3271 - 3279
  • [47] Unique ESR1 and ESR2 estrogen receptor gene variants associated with altered risk of triple-negative breast cancer: A case-control study
    Sghaier, Ikram
    Zidi, Sabrina
    El-Ghali, Rabeb M.
    Daldoul, Amira
    Aimagambetova, Gulzhanat
    Almawi, Wassim Y.
    GENE, 2023, 851
  • [48] Clinicopathological characteristics and long-term prognosis of triple-negative breast cancer patients with HER2-Low expression: a retrospective propensity score-matched cohort study
    Liu, Xin
    Zhao, Kaihua
    Zhang, Ziyan
    Liu, Meiyan
    Chu, Hongwu
    Zou, Xiao
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 151 (01)
  • [49] Long non-coding RNA heart and neural crest derivatives expressed 2-antisense RNA 1 overexpression inhibits the proliferation of cancer cells by reducing RUNX2 expression in triple-negative breast cancer
    Wei, Min
    Liu, Lei
    Wang, Zhiwei
    ONCOLOGY LETTERS, 2019, 18 (06) : 6775 - 6780
  • [50] Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto)
    Untch, M.
    Schneeweiss, A.
    Salat, C.
    Rezai, M.
    Zahm, D-M.
    Klare, P.
    Blohmer, J-U.
    Tesch, H.
    Khandan, F.
    Fasching, P. A.
    Jackisch, C.
    Nekljudova, V.
    von Minckwitz, G.
    Loibl, S.
    ANNALS OF ONCOLOGY, 2017, 28